Greenwich LifeSciences (GLSI) Non-Current Assets (2019 - 2024)

Greenwich LifeSciences (GLSI) posted Non-Current Assets of $1779.0 for Q4 2024, down 86.84% on a QoQ basis from $13518.0 in Q3 2021.

Greenwich LifeSciences (GLSI) Non-Current Assets (2019 - 2024) Analysis & Trends

Greenwich LifeSciences' Non-Current Assets history runs 4 years deep, the most recent figure standing at $1779.0 for Q4 2024.

Quarterly Non-Current Assets changed N/A year-over-year to $1779.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $29718.0 (down 34.02% YoY) and the FY2024 annual result came in at $1779.0, changed N/A from the prior year.
Non-Current Assets was $1779.0 for Q4 2024 at Greenwich LifeSciences, down from $13518.0 in the prior quarter.
Across five years, Non-Current Assets topped out at $17130.0 in Q3 2020 and bottomed at $1779.0 in Q4 2024.
A 3-year average of $13066.5 and a median of $14872.5 in 2021 frame the typical range for Non-Current Assets.
Annual changes were most pronounced in 2020 — Non-Current Assets declined 18.19% — and 2021, when it decreased 21.09%.
Greenwich LifeSciences' Non-Current Assets stood at $16227.0 in 2020, then fell by 16.69% to $13518.0 in 2021, then sank by 86.84% to $1779.0 in 2024.
Business Quant data shows GLSI's Non-Current Assets at $1779.0 in Q4 2024, $13518.0 in Q3 2021, and $14421.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	21.65 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	5.83 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	1.95 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	3.95 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	14.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	22.66 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	289.41 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.96 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	285.82 Mn
10	Greenwich LifeSciences	178.53 Mn	178.53 Mn	-	-

Download Data